08048035996
Premium Exporter of Genuine TRASTUREL 440mg Injection from India to Singapore –Orchard |Phoenix Exim

1. General Information

TRASTUREL 440 mg Injection is an anti-cancer biological medicine containing trastuzumab. Trastuzumab is a targeted monoclonal antibody that acts against the HER2 (human epidermal growth factor receptor 2) protein.

Some cancer cells have abnormally high levels of HER2, which can promote cancer-cell growth. Trastuzumab specifically binds to HER2 and helps inhibit HER2-related signaling and cancer-cell growth.

  • Brand: Trasturel
  • Strength: 440 mg
  • Active ingredient: Trastuzumab
  • Dosage form: Injection / powder for concentrate for intravenous infusion
  • Therapeutic category: Anticancer / targeted biological therapy
  • Route: Intravenous infusion
  • Prescription: Required
  • Administration: By a qualified healthcare professional
  • Storage: Generally refrigerated at 2°C–8°C; follow the product-specific packaging and prescribing information and do not freeze.

2. Product Information

TRASTUREL 440 mg Injection contains 440 mg of trastuzumab in a vial. Trastuzumab 440 mg presentations are formulated as a powder for preparation of an intravenous infusion. The exact excipients and supplied diluent can vary by manufacturer, so the product's package insert should be checked before preparation.

Trastuzumab treatment is selected according to the patient's cancer type, HER2 status, previous treatment, body weight, overall health, and treatment protocol.

3. Uses of TRASTUREL 440 mg Injection

TRASTUREL may be used as part of treatment for certain HER2-positive cancers, including:

  • HER2-positive breast cancer
  • Certain early-stage HER2-positive breast cancers
  • HER2-positive metastatic breast cancer
  • HER2-positive gastric cancer
  • HER2-positive gastroesophageal-junction adenocarcinoma

The precise indication and treatment combination depend on the patient's diagnosis and the oncologist's treatment plan.

4. Benefits of This Medicine

The potential therapeutic benefits of trastuzumab include:

  • Provides targeted treatment against HER2-positive cancer cells.
  • Helps inhibit HER2-mediated cancer-cell growth.
  • May slow disease progression in appropriate HER2-positive cancers.
  • Can be used in different treatment settings, including selected early-stage and advanced/metastatic cancers.
  • May be prescribed alone or together with other anticancer treatments depending on the cancer and treatment protocol.

The expected benefit varies from patient to patient and should be assessed by the treating oncologist.

5. Side Effects of TRASTUREL 440 mg Injection

Like other anticancer medicines, trastuzumab can cause side effects. Possible reactions include:

  • Infusion-related reactions
  • Fever and chills
  • Fatigue
  • Nausea or vomiting
  • Diarrhoea
  • Headache
  • Cough
  • Rash
  • Muscle or bone pain
  • Back pain
  • Abdominal discomfort
  • Swelling or edema
  • Injection/infusion-site reactions

Trastuzumab can also cause serious reactions, including heart problems, severe infusion or hypersensitivity reactions, and pulmonary toxicity.

6. Common Side Effects

Some commonly reported effects include:

  1. Chills
  2. Fever
  3. Fatigue
  4. Nausea
  5. Vomiting
  6. Diarrhoea
  7. Headache
  8. Cough
  9. Muscle or bone pain
  10. Rash
  11. Infusion-related reactions
  12. Swelling

Seek immediate medical attention for severe breathing difficulty, serious allergic symptoms, chest symptoms, marked swelling, or other severe or unusual reactions.

7. How to Use TRASTUREL 440 mg Injection

TRASTUREL 440 mg Injection must not be self-administered.

It is prepared and administered as an intravenous infusion by trained healthcare professionals. The dosage and treatment interval are determined by the oncologist according to the patient's body weight, cancer type, HER2 status, treatment regimen, and clinical condition.

The medicine should be prepared according to the manufacturer's instructions and administered in an appropriate clinical setting.

Do not change the dose, frequency, or duration of treatment without the oncologist's advice.

8. How TRASTUREL 440 mg Injection Works

TRASTUREL contains trastuzumab, a monoclonal antibody that specifically targets the HER2 protein.

In some cancers, excessive HER2 signaling encourages cancer cells to grow and divide. Trastuzumab binds to HER2 and interferes with this signaling, helping inhibit the growth and survival of HER2-positive cancer cells. It can also stimulate immune-mediated mechanisms against cells expressing HER2.

9. Safety Advice for This Medicine

  • Use TRASTUREL only under the supervision of an oncologist or qualified healthcare professional.
  • Confirm that the cancer has been appropriately evaluated for HER2 status before treatment.
  • Tell your doctor about any previous or ongoing cancer treatments.
  • Inform your doctor about any history of heart disease or reduced heart function, because trastuzumab can affect cardiac function.
  • Tell your doctor about existing lung or breathing problems.
  • Inform your healthcare professional about all medicines and treatments you are receiving.
  • Trastuzumab may cause serious embryo-fetal toxicity; patients who are pregnant or planning pregnancy should discuss this with their doctor before treatment.
  • Breastfeeding should also be discussed with the treating healthcare professional.
  • Store the product according to the manufacturer's instructions, generally under refrigerated conditions for the relevant presentation.
  • Do not freeze the medicine.
  • Do not use a vial if its packaging is damaged or the product has been improperly stored.
  • Because this is a prescription oncology medicine, purchase, export, import, and administration should comply with applicable regulations.

10. Frequently Asked Questions (FAQs)

Q1. What is TRASTUREL 440 mg Injection?

TRASTUREL 440 mg Injection is a prescription anticancer medicine containing trastuzumab 440 mg, used for certain HER2-positive cancers.

Q2. What is the active ingredient in TRASTUREL?

The active ingredient is trastuzumab 440 mg.

Q3. What cancers can trastuzumab be used for?

Depending on the approved indication and treatment protocol, trastuzumab can be used for certain HER2-positive breast cancers and HER2-positive gastric or gastroesophageal-junction cancers.

Q4. Can I administer TRASTUREL at home?

No. TRASTUREL should be prepared and administered as an intravenous infusion by an appropriately trained healthcare professional.

Q5. Does TRASTUREL require refrigeration?

The product should generally be stored under refrigerated conditions, commonly 2°C–8°C, according to its specific product information. Do not freeze.

Q6. Can TRASTUREL be replaced with another trastuzumab brand?

There are other 440 mg trastuzumab products available in India. However, switching between products should be done only after confirmation by the treating physician/pharmacist.

Q7. Does trastuzumab affect the heart?

Yes. Trastuzumab treatment can cause a reduction in cardiac function and cardiomyopathy in some patients, so appropriate cardiac monitoring may be required.

Q8. Is TRASTUREL suitable for every cancer patient?

No. It is specifically used for cancers in which trastuzumab is clinically appropriate, particularly cancers demonstrating HER2 positivity. Treatment suitability must be determined by an oncologist.

Q9. What should I do if I experience a severe reaction during infusion?

Tell the healthcare professional immediately. Severe infusion reactions, breathing problems, allergic reactions, or cardiac symptoms require prompt medical assessment.

Q10. Is TRASTUREL a chemotherapy medicine?

Trastuzumab is a targeted biological therapy/monoclonal antibody, rather than a conventional cytotoxic chemotherapy drug. It may nevertheless be used in combination with chemotherapy or other cancer treatments.

11. Substitutes for TRASTUREL 440 mg Injection

Possible alternatives containing the same active ingredient trastuzumab 440 mg include products such as:

  • Herclon 440 mg Injection
  • Hertraz 440 mg Injection
  • Eleftha 440 mg Injection
  • Herhope 440 mg Injection
  • Hersima 440 mg Injection
  • HERMAB 440 mg Injection

Indian medicine listings identify these as trastuzumab 440 mg products from different manufacturers.

Important: A substitute should not be selected solely on brand name or price. The treating oncologist or pharmacist should confirm the appropriate product, strength, formulation, storage requirements, and interchangeability before any switch.

12. SEO Keywords

Primary Keywords

  • Trasturel 440 mg Injection
  • Trasturel 440 mg Injection exporter
  • Trasturel 440 mg Injection supplier
  • Trasturel 440 mg Injection from India
  • Trastuzumab 440 mg Injection exporter
  • Trastuzumab 440 mg Injection supplier
  • Trastuzumab 440 mg wholesale supplier
  • Trastuzumab 440 mg oncology medicine
  • HER2 positive cancer medicine supplier
  • Trasturel 440 mg medicine exporter India

Long-Tail B2B Keywords

  • Buy Trasturel 440 mg Injection from India
  • Trasturel 440 mg Injection pharmaceutical exporter from India
  • Trasturel 440 mg Injection wholesale supplier India
  • Trastuzumab 440 mg Injection exporter from Nagpur India
  • Genuine Trasturel 440 mg Injection supplier from India
  • Trasturel 440 mg Injection international medicine supplier
  • Trastuzumab 440 mg Injection bulk supply from India
  • Trasturel 440 mg Injection for international pharmaceutical buyers
  • HER2 positive breast cancer medicine exporter India
  • Trastuzumab 440 mg oncology injection supplier India
  • Trasturel 440 mg Injection supplier for USA
  • Trasturel 440 mg Injection supplier for UK
  • Trasturel 440 mg Injection supplier for Australia
  • Trasturel 440 mg Injection supplier for Singapore
  • Trasturel 440 mg Injection supplier for Canada
  • Trasturel 440 mg Injection supplier for South Korea
  • Trasturel 440 mg Injection supplier for UAE
  • Phoenix Exim Trasturel 440 mg Injection supplier
  • Phoenix Exim pharmaceutical exporter Nagpur India
  • Trastuzumab 440 mg Injection international export supplier


Aug 20th, 2026 3:11 PM

Keywords